This issue introduces a first-in-class oral treatment for heart failure – sacubitril/valsartan. It provides a comprehensive background to heart failure treatment in the UK, the pathophysiology of the disease and the pivotal trial data on the new drug.
Articles give perspectives on the role of the GP, practice nurse, pharmacist and commissioner in using the drug, together with useful online heart failure resources for health professionals and patients.
Click on the link below for sacubitril/valsartan (Entresto▼™) clinical trial data, patient management guidelines and interviews with heart failure experts. The website aims to aid implementation of NICE and SMC guidance on managing heart failure with Entresto. https://www.action-hf.co.uk/. action-hf.co.uk is a promotional resource funded by Novartis Pharmaceuticals UK Ltd.
BJPCN, Volume 13, Number 1, Oct-Nov-Dec 2016
PCCJ, Volume 9 Number 1, Oct-Nov-Dec 2016
